<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nijmegen breakage syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nijmegen breakage syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nijmegen breakage syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Gennery, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A number of human genetic disorders cause chromosomal breakage, which is characterized by genome instability that occurs in the basal state (spontaneously) or in response to deoxyribonucleic acid (DNA) damaging agents  (<a class="graphic graphic_table graphicRef82574" href="/z/d/graphic/82574.html" rel="external">table 1</a>). These disorders cause defects in the recognition and/or repair of damage to DNA inflicted by different agents. In most cases, the genome instability is associated with immunodeficiency, a predisposition to develop cancer, and premature aging [<a href="#rid1">1</a>].</p><p>This topic review will discuss Nijmegen breakage syndrome (NBS; MIM #251260), which is a chromosomal breakage syndrome associated with immunodeficiency [<a href="#rid2">2,3</a>]. Discussions relating to similar disorders are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a> and  <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">"Bloom syndrome"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>NBS is a rare disorder. The exact incidence is unknown. Most reported NBS patients have an ethnic origin from Eastern Europe, notably Poland, the Czech Republic, and Ukraine [<a href="#rid4">4,5</a>]. One study analyzed newborn screening cards for the most common <em>NBS</em> variant (657del5) [<a href="#rid5">5</a>]. The prevalence of this variant ranged from 1 in 154 to 1 in 190 in three Slavic populations compared with 1 in 866 in a German population reported in a separate study [<a href="#rid6">6</a>]. The incidence of NBS was estimated to be 1 in 95,000 livebirths in Czechoslovakia [<a href="#rid5">5</a>]. A subsequent study of an Eastern Slavic population found a prevalence of 2.3 per 1,000,000 in Belarus, 1.3 per 1,000,000 in Ukraine, and 0.7 per 1,000,000 in Russia for the 657del5 variant [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>NBS is an autosomal recessive chromosomal instability disorder that is caused by pathogenic variants in the nibrin <em>(NBN)</em> gene on 8q21 that encodes the protein nibrin (MIM #602667) [<a href="#rid8">8</a>]. The most common variant in patients of Eastern European descent is hypomorphic, leading to a partially functional protein [<a href="#rid9">9</a>]. Other variants are more common in different populations [<a href="#rid3">3</a>].</p><p>Nibrin forms a complex with meiotic recombination 11 (MRE11, the protein mutated in ataxia-telangiectasia-like disorder) and RAD50 (a protein involved in DNA double-strand break repair) and then rapidly localizes to the site of DNA double-strand breaks. DNA breaks are not efficiently repaired in the absence of nibrin [<a href="#rid10">10-12</a>]. This protein complex is also involved in meiotic recombination and telomere maintenance [<a href="#rid13">13-15</a>]. In addition, nibrin plays a role in the initiation of base excision repair after oxidative or alkylating stress [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>NBS is characterized by progressive, severe microcephaly and a "bird-like" face; intrauterine growth retardation and short stature; immunodeficiency with recurrent sinopulmonary infections; a predisposition to malignancy, predominantly lymphoid malignancies; and primary ovarian insufficiency (premature ovarian failure) in females [<a href="#rid2">2,3,17</a>].</p><p>There is a distinct pattern of malformations:</p><p class="bulletIndent1"><span class="glyph">●</span>Virtually all patients have severe microcephaly, well below the third percentile and 10 to 12 cm in diameter less than mean for age [<a href="#rid17">17</a>]. Microcephaly is present at birth in 75 percent of cases and develops in the rest of patients during early infancy. The microcephaly is progressive and is associated with a decline in cognitive skills that results in mild-to-moderate intellectual disability by 7 to 10 years of age. Autopsy studies and cranial magnetic resonance imaging (MRI) have attributed this problem to stunted brain growth, with particularly severe effects on the frontal lobes and corpus callosum [<a href="#rid18">18,19</a>]. The cerebellum appears to be normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with NBS also have abnormal facies with a sloping forehead, receding mandible, prominent mid-face, long nose, and upward slant of the palpebral fissures. These facial features become more prominent as the microcephaly progresses and are recognizable beginning at approximately three years of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other malformations occur in as many as 50 percent of patients. These include clinodactyly and syndactyly, atresia/stenosis along the gastrointestinal tract, choanal atresia, cleft lip and palate, hydronephrosis, and hip dysplasia. Hypergonadotropic hypogonadism is common in affected males and leads to infertility [<a href="#rid20">20</a>]. Ovarian dysgenesis and premature ovarian failure occur in affected females [<a href="#rid21">21</a>].</p><p></p><p>Patients may be small for gestational age at birth, and growth retardation typically occurs in the first two years of life. After that, growth velocity usually returns to normal. However, height is usually below the third percentile because of the initial growth delay.</p><p>Many patients develop café-au-lait spots and depigmented skin lesions. Porokeratosis, a hyperkeratotic disorder, and cutaneous noncaseating granulomas have been reported in patients with NBS [<a href="#rid22">22-24</a>]. Isolated pulmonary granuloma are described [<a href="#rid25">25</a>]. Rubella virus has been identified in granulomatous lesions in patients with NBS and other inborn errors of immunity (primary immunodeficiencies) [<a href="#rid26">26</a>].</p><p>Cancer is the leading cause of death for patients with NBS, with 40 percent of patients developing a malignancy before 20 years of age [<a href="#rid27">27,28</a>]. The majority of cancers are lymphomas [<a href="#rid28">28,29</a>], but there have been case reports of glioma, rhabdomyosarcoma, and medulloblastoma [<a href="#rid30">30-32</a>]. Patients appear to have enhanced radiosensitivity [<a href="#rid33">33</a>]. An increased susceptibility to malignancy has been reported in heterozygotes, although they appear to be normal in other respects [<a href="#rid34">34-36</a>]. Regional differences in environmental factors can affect age of onset of tumors [<a href="#rid37">37</a>]. A study of 241 patients with NBS found a cumulative cancer incidence of 40 percent at 10 years and 78 percent at 20 years of follow-up, with the majority of tumors being non-Hodgkin lymphomas [<a href="#rid29">29</a>]. Another study found differences in the age of onset of cancer (predominantly lymphoma) related to geographic area [<a href="#rid37">37</a>]. Patients in the Czech Republic and Slovakia had an earlier onset of malignancy than a similar cohort from Poland. All patients were homozygous for the Slavic founder mutation. Higher naturally occurring background radiation in the Czech Republic and Slovakia may account for the earlier onset of tumors. (See  <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">"Radiation-associated sarcomas", section on 'Genetic predisposition'</a>.)</p><p>Many patients suffer from recurrent upper and lower respiratory tract infections (pneumonia, bronchitis, sinusitis, otitis media, and mastoiditis). Chronic lung disease with bronchiectasis is the second leading cause of death [<a href="#rid27">27</a>]. Oral candidiasis and gingival hyperplasia have been reported [<a href="#rid38">38</a>]. There are no published reports of opportunistic infections, but there is evidence of more generalized immune dysfunction, with patients exhibiting autoimmune (immune thrombocytopenia and hemolytic anemia) and chronic inflammatory (childhood sarcoidosis) disorders at much higher than expected frequencies [<a href="#rid27">27,39</a>]. Lymphocytic interstitial pneumonitis is described [<a href="#rid24">24</a>].</p><p>Primary ovarian insufficiency is common in females with NBS [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H5"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>Immunodeficiency is common in NBS patients [<a href="#rid27">27,40</a>]. One-third of patients are agammaglobulinemic. As many as 80 percent of the others have absent or low levels of one or more immunoglobulin classes or immunoglobulin G (IgG) subclasses [<a href="#rid27">27,41</a>].</p><p>The majority of patients are lymphopenic, with relatively similar diminution of CD4+ and CD8+ T cells [<a href="#rid27">27</a>] as well as decreased CD19+ cells due to a quantitative VDJ (variable, diversity, and joining segments) recombination deficiency [<a href="#rid42">42</a>] and a reduction in class-switched memory B cells [<a href="#rid43">43</a>]. Circulating T cells comprise a higher frequency of CD57+ CD28- cells, indicative of senescence [<a href="#rid44">44</a>], and of CD279, indicative of T lymphocyte exhaustion [<a href="#rid45">45</a>]. In addition, most patients have reduced in vitro proliferative responses to mitogens [<a href="#rid27">27</a>]. At autopsy, the thymus is small and devoid of Hassall's corpuscles, suggesting dysplasia [<a href="#rid18">18</a>]. Lymph nodes have normal architecture, but lymphoid follicles are small, and germinal centers are reduced in number.</p><p>The characteristic laboratory abnormality in NBS is chromosome instability. Cultured T cells show an extremely low mitotic index, making cytogenetic analysis difficult, but structural chromosomal aberrations are present in 10 to 35 percent of metaphases [<a href="#rid46">46</a>]. Most of the rearrangements occur in chromosomes 7 and 14 at the locations of immunoglobulin and T cell receptor (TCR) genes and may be present in as many as one-third of tested lymphocytes [<a href="#rid2">2</a>].</p><p>Radiation hypersensitivity is documented in both lymphocytes and fibroblasts from patients with NBS [<a href="#rid47">47</a>]. The extent of sensitivity is comparable with that observed in patients with ataxia-telangiectasia.</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The most prominent feature of NBS is severe microcephaly. Although the differential diagnosis of microcephaly is extensive, the relatively mild intellectual disability and characteristic facies should point to the diagnosis of NBS. (See  <a class="medical medical_review" href="/z/d/html/2839.html" rel="external">"Microcephaly in infants and children: Etiology and evaluation", section on 'Microcephaly'</a>.)</p><p>A range of laboratory tests is required for confirmation of the diagnosis. Demonstration of chromosomal rearrangements typically involving chromosomes 7 and 14, as well as chromosomal hypersensitivity to X-irradiation, suggests NBS or an associated disorder such as DNA ligase IV deficiency or Cernunnos/XRCC4-like factor (XLF) deficiency. Immunoblotting and molecular genetic testing are required to confirm the diagnosis. The 657 del 5 mutation of the <em>NBS</em> gene on 8q21 is present in approximately 85 percent of cases in the United States, simplifying the task of genetic confirmation in many cases [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'XRCC4 and DNA ligase IV'</a> and  <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'Cernunnos/XLF'</a>.)</p><p>Some patients with NBS have low numbers of T cells at birth and consequently have low T cell receptor excision circles (TRECs), which are measured on the newborn screening assay for severe combined immunodeficiency (SCID) and other T cell defects that result in T cell lymphopenia [<a href="#rid48">48</a>]. Thus, NBS can be detected on newborn screening in countries that include the TREC assay. (See  <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">"Newborn screening for inborn errors of immunity", section on 'Screening for SCID and other T cell defects'</a>.)</p><p>Prenatal diagnosis and carrier detection using molecular genetic testing is available for those with affected family members whose pathogenic variants are known.</p><p>A list of laboratories offering clinical testing for NBS is available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=3957" target="_blank">Genetic Testing Registry (GTR) website</a>.</p><p class="headingAnchor" id="H7"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>This disease shares the laboratory feature of radiation hypersensitivity observed with ataxia-telangiectasia and ataxia-telangiectasia-like disease. However, NBS can be distinguished from these disorders in that there is no neurodegeneration, but rather microcephaly with mild-to-moderate intellectual disability. In addition, unlike these two disorders, NBS patients do not have telangiectasia, and serum alpha-fetoprotein levels are normal. (See  <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a>.)</p><p>Development delay, microcephaly, cancer predisposition, and immune abnormalities are also observed in Fanconi anemia. In two patients with suspected Fanconi anemia, the correct diagnosis of NBS was only discovered after chromosomal gene arrangement studies and sequence of the NBS gene [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia", section on 'Clinical features'</a>.)</p><p>Deficiency of RAD50, which is part of the MRE11/RAD50/NBS (MRN) complex (see <a class="local">'Pathogenesis'</a> above), presents with clinical features similar to NBS (eg, microcephaly, "bird-like" face, short stature, and intellectual disability) [<a href="#rid50">50</a>]. However, the first patient reported with RAD50 deficiency (also called Nijmegen breakage syndrome-like disorder [NBSLD]; MIM #613078) had normal immunoglobulin levels, did not have a history of serious infections, and had not developed malignancy by age 23 years despite demonstration of chromosomal instability and radiosensitivity.</p><p>Other syndromes sharing some clinical features with NBS that are associated with chromosomal instability and increased susceptibility to malignancy include DNA ligase I deficiency [<a href="#rid51">51</a>], DNA ligase IV deficiency [<a href="#rid52">52</a>], Cernunnos/XRCC4-like factor (XLF) deficiency [<a href="#rid53">53</a>], Bloom syndrome, and Seckel syndrome [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'XRCC4 and DNA ligase IV'</a> and  <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'Cernunnos/XLF'</a> and  <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">"Bloom syndrome"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There is no specific treatment for NBS.</p><p>Sinopulmonary infections are most common and may lead to bronchiectasis. Subjects should be evaluated for immunodeficiency and treated as appropriate with antibiotic prophylaxis and, in severe antibody deficiency, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement. Live vaccines should be avoided. Allogeneic hematopoietic cell transplantation (HCT) has been performed in patients with NBS.</p><p>One case series reported on outcomes of HCT for DNA double-strand break repair disorders [<a href="#rid55">55</a>]. This series included 26 patients with NBS, 19 of whom were alive at the time of last follow-up. Malignancies were the most common indication for HCT. Two patients received preemptive HCT because of their severe combined immunodeficiency (SCID) phenotype. Those treated with myeloablative conditioning had poorer survival compared with patients who received a reduced-intensity conditioning regimen, with increased frequency of early death due to transplant-related toxicity. A single-center study in a series of patients with the 657del5 mutation who received a T cell receptor (TCR) alpha-beta/CD19-depleted graft demonstrated that toxicity outcomes after using submyeloablative doses of <a class="drug drug_general" data-topicid="134625" href="/z/d/drug information/134625.html" rel="external">treosulfan</a> were similar to low-dose <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a>, with improved engraftment [<a href="#rid56">56</a>]. Other series (which include some of the patients in the first case series described [<a href="#rid55">55</a>]) also demonstrate the utility of HCT [<a href="#rid24">24,28,57</a>]. (See  <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a> and  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>.)</p><p>Patients with NBS have a high risk of developing malignancy, predominantly lymphomas, with over 40 percent developing a malignancy by the age of 20 years. Parents/caregivers should be counseled about the presenting signs of lymphoma and other malignancies. Preliminary data suggest that monitoring for appearance of certain biomarkers that can precede malignancy (eg, monoclonal proteins, immunoglobulin/TCR gene rearrangements, and viral infections including Epstein-Barr virus and hepatitis) may be useful [<a href="#rid58">58</a>]. In one study, patients diagnosed with cancer who received HCT had higher 20-year overall survival than those who did not receive HCT. In the group of patients who underwent preemptive HCT, only one patient developed cancer, a rate seven times lower compared with nontransplanted patients [<a href="#rid29">29</a>].</p><p>Patients with NBS have increased sensitivity to both radiation therapy and chemotherapy, which complicates treatment of malignancies [<a href="#rid33">33,59</a>]. Radiotherapy should be avoided if possible, but, if necessary, significantly decreased doses should be used. Several patients with lymphoma have been treated successfully with decreased doses of chemotherapy [<a href="#rid60">60-62</a>]. Patients with malignancy who have a worse prognosis typically also have a significant coexistent immunodeficiency. Less toxic chemotherapy regimens should be use for this group, if possible, with the addition of infection prophylaxis [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">"Radiation-associated sarcomas", section on 'Genetic predisposition'</a>.)</p><p>Females with NBS should be monitored for primary ovarian insufficiency [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H9"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Life expectancy is reduced because of the tendency for NBS patients to develop malignancies at a young age. In a report by the International Nijmegen Breakage Syndrome Study Group published in 2000, only 8 out of 22 known cases of NBS with malignancy were still alive at the end of an unstated follow-up period. The median age at the time of death was seven years (range 2 to 21 years) [<a href="#rid27">27</a>]. Other patients succumb to fatal infections. A subsequent report of 149 patients with NBS gave an overall survival probability of 35 percent by 30 years, with the oldest cohort member reported as 33.7 years of age, with a median age at death of 11 years (range 2 to 33.6 years) [<a href="#rid28">28</a>]. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H1716930717"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Nijmegen breakage syndrome (NBS) is an autosomal recessive disorder characterized by chromosomal instability and radiation hypersensitivity, immunodeficiency, short stature, microcephaly and a "bird-like" face, and a predisposition to malignancy. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – NBS is caused by pathogenic variants in the nibrin <em>(NBN)</em> gene, which encodes for the protein, nibrin, which is involved in double-strand deoxyribonucleic acid (DNA) break repair, meiotic recombination, and telomere maintenance. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The characteristic clinical features of NBS include severe microcephaly and a "bird-like" face, short stature, immunodeficiency with recurrent sinopulmonary infections, and a predisposition to malignancy. Carriers also have an increased risk of malignancy. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – The characteristic laboratory abnormality in NBS is chromosome instability. Most patients are lymphopenic, and approximately one-third have agammaglobulinemia. Alpha-fetoprotein levels are normal. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis is based upon the presence of characteristic clinical manifestation and confirmed by the demonstration of chromosomal rearrangements typically involving chromosomes 7 and 14, as well as chromosomal hypersensitivity to X-irradiation. The diagnosis can also be confirmed by identification of pathogenic variants in the <em>NBN</em> gene. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis includes ataxia-telangiectasia, Fanconi anemia, RAD50 (a protein involved in DNA double-strand break repair) deficiency, DNA ligase I and IV defects, Cernunnos/XLF (X-ray repair, complementing defective, in Chinese hamster, 4 [XRCC4]-like factor [XLF]) deficiency, Bloom syndrome, and Seckel syndrome. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There is no specific treatment for NBS. Subjects should be evaluated for immunodeficiency and treated as appropriate. Parents/caregivers should be counseled about the presenting signs of lymphoma and other malignancies. Radiation therapy should be avoided, if possible. Hematopoietic cell transplantation (HCT) is an option for selected patients and may reduce the risk of developing malignancy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H1343592168"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kamenisch Y, Berneburg M. Progeroid syndromes and UV-induced oxidative DNA damage. J Investig Dermatol Symp Proc 2009; 14:8.</a></li><li><a class="nounderline abstract_t">Chrzanowska KH, Gregorek H, Dembowska-Bagińska B, et al. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis 2012; 7:13.</a></li><li class="breakAll">Gene Reviews. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1176/ (Accessed on March 21, 2012).</li><li><a class="nounderline abstract_t">Weemaes CM, Hustinx TW, Scheres JM, et al. A new chromosomal instability disorder: the Nijmegen breakage syndrome. Acta Paediatr Scand 1981; 70:557.</a></li><li><a class="nounderline abstract_t">Varon R, Seemanova E, Chrzanowska K, et al. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet 2000; 8:900.</a></li><li><a class="nounderline abstract_t">Carlomagno F, Chang-Claude J, Dunning AM, Ponder BA. Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer. Genes Chromosomes Cancer 1999; 25:393.</a></li><li><a class="nounderline abstract_t">Sharapova SO, Pashchenko OE, Bondarenko AV, et al. Geographical Distribution, Incidence, Malignancies, and Outcome of 136 Eastern Slavic Patients With Nijmegen Breakage Syndrome and NBN Founder Variant c.657_661del5. Front Immunol 2020; 11:602482.</a></li><li><a class="nounderline abstract_t">Antoccia A, Kobayashi J, Tauchi H, et al. Nijmegen breakage syndrome and functions of the responsible protein, NBS1. Genome Dyn 2006; 1:191.</a></li><li><a class="nounderline abstract_t">Lins S, Kim R, Krüger L, et al. Clinical variability and expression of the NBN c.657del5 allele in Nijmegen Breakage Syndrome. Gene 2009; 447:12.</a></li><li><a class="nounderline abstract_t">Carney JP, Maser RS, Olivares H, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998; 93:477.</a></li><li><a class="nounderline abstract_t">Yuan J, Chen J. MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX. J Biol Chem 2010; 285:1097.</a></li><li><a class="nounderline abstract_t">Williams RS, Dodson GE, Limbo O, et al. Nbs1 flexibly tethers Ctp1 and Mre11-Rad50 to coordinate DNA double-strand break processing and repair. Cell 2009; 139:87.</a></li><li><a class="nounderline abstract_t">Brugmans L, Verkaik NS, Kunen M, et al. NBS1 cooperates with homologous recombination to counteract chromosome breakage during replication. DNA Repair (Amst) 2009; 8:1363.</a></li><li><a class="nounderline abstract_t">Attwooll CL, Akpinar M, Petrini JH. The mre11 complex and the response to dysfunctional telomeres. Mol Cell Biol 2009; 29:5540.</a></li><li><a class="nounderline abstract_t">Deng Y, Guo X, Ferguson DO, Chang S. Multiple roles for MRE11 at uncapped telomeres. Nature 2009; 460:914.</a></li><li><a class="nounderline abstract_t">Sagan D, Müller R, Kröger C, et al. The DNA repair protein NBS1 influences the base excision repair pathway. Carcinogenesis 2009; 30:408.</a></li><li><a class="nounderline abstract_t">Digweed M, Sperling K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 2004; 3:1207.</a></li><li><a class="nounderline abstract_t">Van de Kaa CA, Weemaes CM, Wesseling P, et al. Postmortem findings in the Nijmegen breakage syndrome. Pediatr Pathol 1994; 14:787.</a></li><li><a class="nounderline abstract_t">Bekiesińska-Figatowska M, Chrzanowska KH, Sikorska J, et al. Cranial MRI in the Nijmegen breakage syndrome. Neuroradiology 2000; 42:43.</a></li><li><a class="nounderline abstract_t">Warcoin M, Lespinasse J, Despouy G, et al. Fertility defects revealing germline biallelic nonsense NBN mutations. Hum Mutat 2009; 30:424.</a></li><li><a class="nounderline abstract_t">Chrzanowska KH, Szarras-Czapnik M, Gajdulewicz M, et al. High prevalence of primary ovarian insufficiency in girls and young women with Nijmegen breakage syndrome: evidence from a longitudinal study. J Clin Endocrinol Metab 2010; 95:3133.</a></li><li><a class="nounderline abstract_t">Wolf EK, Shwayder TA. Nijmegen breakage syndrome associated with porokeratosis. Pediatr Dermatol 2009; 26:106.</a></li><li><a class="nounderline abstract_t">Yoo J, Wolgamot G, Torgerson TR, Sidbury R. Cutaneous noncaseating granulomas associated with Nijmegen breakage syndrome. Arch Dermatol 2008; 144:418.</a></li><li><a class="nounderline abstract_t">Deripapa E, Balashov D, Rodina Y, et al. Prospective Study of a Cohort of Russian Nijmegen Breakage Syndrome Patients Demonstrating Predictive Value of Low Kappa-Deleting Recombination Excision Circle (KREC) Numbers and Beneficial Effect of Hematopoietic Stem Cell Transplantation (HSCT). Front Immunol 2017; 8:807.</a></li><li><a class="nounderline abstract_t">Marczak H, Heropolitańska-Pliszka E, Langfort R, et al. Nijmegen Breakage Syndrome Complicated With Primary Pulmonary Granulomas. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">Buchbinder D, Hauck F, Albert MH, et al. Rubella Virus-Associated Cutaneous Granulomatous Disease: a Unique Complication in Immune-Deficient Patients, Not Limited to DNA Repair Disorders. J Clin Immunol 2019; 39:81.</a></li><li><a class="nounderline abstract_t">Nijmegen breakage syndrome. The International Nijmegen Breakage Syndrome Study Group. Arch Dis Child 2000; 82:400.</a></li><li><a class="nounderline abstract_t">Wolska-Kuśnierz B, Gregorek H, Chrzanowska K, et al. Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options - a Retrospective Analysis. J Clin Immunol 2015; 35:538.</a></li><li><a class="nounderline abstract_t">Wolska-Kusnierz B, Pastorczak A, Fendler W, et al. Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome. Clin Cancer Res 2021; 27:575.</a></li><li><a class="nounderline abstract_t">Gładkowska-Dura M, Dzierzanowska-Fangrat K, Dura WT, et al. Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation. J Pathol 2008; 216:337.</a></li><li><a class="nounderline abstract_t">Ciara E, Piekutowska-Abramczuk D, Popowska E, et al. Heterozygous germ-line mutations in the NBN gene predispose to medulloblastoma in pediatric patients. Acta Neuropathol 2010; 119:325.</a></li><li><a class="nounderline abstract_t">Huang J, Grotzer MA, Watanabe T, et al. Mutations in the Nijmegen breakage syndrome gene in medulloblastomas. Clin Cancer Res 2008; 14:4053.</a></li><li><a class="nounderline abstract_t">Pollard JM, Gatti RA. Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol Biol Phys 2009; 74:1323.</a></li><li><a class="nounderline abstract_t">Seemanová E. An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability. Mutat Res 1990; 238:321.</a></li><li><a class="nounderline abstract_t">Seemanová E, Jarolim P, Seeman P, et al. Cancer risk of heterozygotes with the NBN founder mutation. J Natl Cancer Inst 2007; 99:1875.</a></li><li><a class="nounderline abstract_t">di Masi A, Antoccia A. NBS1 Heterozygosity and Cancer Risk. Curr Genomics 2008; 9:275.</a></li><li><a class="nounderline abstract_t">Chrzanowska KH, Seemanova E, Varon R, et al. The NBN founder mutation-Evidence for a country specific difference in age at cancer manifestation. Cancer Rep (Hoboken) 2023; 6:e1700.</a></li><li><a class="nounderline abstract_t">Gregorek H, Olczak-Kowalczyk D, Dembowska-Bagińska B, et al. Oral findings in patients with Nijmegen breakage syndrome: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108:e39.</a></li><li class="breakAll">Wegner RF, German JJ, Chrzanpwska KH, et al. Chromosomal instability syndromes other than ataxia-telangiectasia. In: Primary immunodeficiency syndromes: A molecular and genetic approach, Ochs HD, Smith CIE, Puck JM (Eds), Oxford University Press, Oxford 2007. p.432.</li><li><a class="nounderline abstract_t">Chrzanowska KH, Kleijer WJ, Krajewska-Walasek M, et al. Eleven Polish patients with microcephaly, immunodeficiency, and chromosomal instability: the Nijmegen breakage syndrome. Am J Med Genet 1995; 57:462.</a></li><li><a class="nounderline abstract_t">Gregorek H, Chrzanowska KH, Michałkiewicz J, et al. Heterogeneity of humoral immune abnormalities in children with Nijmegen breakage syndrome: an 8-year follow-up study in a single centre. Clin Exp Immunol 2002; 130:319.</a></li><li><a class="nounderline abstract_t">van der Burg M, Pac M, Berkowska MA, et al. Loss of juxtaposition of RAG-induced immunoglobulin DNA ends is implicated in the precursor B-cell differentiation defect in NBS patients. Blood 2010; 115:4770.</a></li><li><a class="nounderline abstract_t">Piątosa B, van der Burg M, Siewiera K, et al. The defect in humoral immunity in patients with Nijmegen breakage syndrome is explained by defects in peripheral B lymphocyte maturation. Cytometry A 2012; 81:835.</a></li><li><a class="nounderline abstract_t">Meijers RWJ, Dzierzanowska-Fangrat K, Zborowska M, et al. Circulating T Cells of Patients with Nijmegen Breakage Syndrome Show Signs of Senescence. J Clin Immunol 2017; 37:133.</a></li><li><a class="nounderline abstract_t">Piatosa B, Wolska-Kuśnierz B, Tkaczyk K, et al. T Lymphocytes in Patients With Nijmegen Breakage Syndrome Demonstrate Features of Exhaustion and Senescence in Flow Cytometric Evaluation of Maturation Pathway. Front Immunol 2020; 11:1319.</a></li><li><a class="nounderline abstract_t">Taalman RD, Hustinx TW, Weemaes CM, et al. Further delineation of the Nijmegen breakage syndrome. Am J Med Genet 1989; 32:425.</a></li><li><a class="nounderline abstract_t">Taalman RD, Jaspers NG, Scheres JM, et al. Hypersensitivity to ionizing radiation, in vitro, in a new chromosomal breakage disorder, the Nijmegen Breakage Syndrome. Mutat Res 1983; 112:23.</a></li><li><a class="nounderline abstract_t">Patel JP, Puck JM, Srinivasan R, et al. Nijmegen breakage syndrome detected by newborn screening for T cell receptor excision circles (TRECs). J Clin Immunol 2015; 35:227.</a></li><li><a class="nounderline abstract_t">Gennery AR, Slatter MA, Bhattacharya A, et al. The clinical and biological overlap between Nijmegen Breakage Syndrome and Fanconi anemia. Clin Immunol 2004; 113:214.</a></li><li><a class="nounderline abstract_t">Waltes R, Kalb R, Gatei M, et al. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet 2009; 84:605.</a></li><li><a class="nounderline abstract_t">Webster AD, Barnes DE, Arlett CF, et al. Growth retardation and immunodeficiency in a patient with mutations in the DNA ligase I gene. Lancet 1992; 339:1508.</a></li><li><a class="nounderline abstract_t">Chistiakov DA, Voronova NV, Chistiakov AP. Ligase IV syndrome. Eur J Med Genet 2009; 52:373.</a></li><li><a class="nounderline abstract_t">Buck D, Malivert L, de Chasseval R, et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 2006; 124:287.</a></li><li><a class="nounderline abstract_t">Griffith E, Walker S, Martin CA, et al. Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling. Nat Genet 2008; 40:232.</a></li><li><a class="nounderline abstract_t">Slack J, Albert MH, Balashov D, et al. Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. J Allergy Clin Immunol 2018; 141:322.</a></li><li><a class="nounderline abstract_t">Laberko A, Sultanova E, Gutovskaya E, et al. Treosulfan-Based Conditioning Regimen in Haematopoietic Stem Cell Transplantation with TCRαβ/CD19 Depletion in Nijmegen Breakage Syndrome. J Clin Immunol 2020; 40:861.</a></li><li><a class="nounderline abstract_t">Albert MH, Gennery AR, Greil J, et al. Successful SCT for Nijmegen breakage syndrome. Bone Marrow Transplant 2010; 45:622.</a></li><li><a class="nounderline abstract_t">Gregorek H, Chrzanowska KH, Dzierzanowska-Fangrat K, et al. Nijmegen breakage syndrome: Long-term monitoring of viral and immunological biomarkers in peripheral blood before development of malignancy. Clin Immunol 2010; 135:440.</a></li><li><a class="nounderline abstract_t">Chistiakov DA, Voronova NV, Chistiakov PA. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol 2008; 47:809.</a></li><li><a class="nounderline abstract_t">Jovanovic A, Minic P, Scekic-Guc M, et al. Successful treatment of hodgkin lymphoma in nijmegen breakage syndrome. J Pediatr Hematol Oncol 2009; 31:49.</a></li><li><a class="nounderline abstract_t">Dembowska-Baginska B, Perek D, Brozyna A, et al. Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). Pediatr Blood Cancer 2009; 52:186.</a></li><li><a class="nounderline abstract_t">Dumic M, Radman I, Krnic N, et al. Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome. Clin Lymphoma Myeloma 2007; 7:590.</a></li><li><a class="nounderline abstract_t">Pastorczak A, Szczepanski T, Mlynarski W, International Berlin-Frankfurt-Munster (I-BFM) ALL host genetic variation working group. Clinical course and therapeutic implications for lymphoid malignancies in Nijmegen breakage syndrome. Eur J Med Genet 2016; 59:126.</a></li></ol></div><div id="topicVersionRevision">Topic 3957 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19675546" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Progeroid syndromes and UV-induced oxidative DNA damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22373003" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nijmegen breakage syndrome (NBS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22373003" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nijmegen breakage syndrome (NBS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7315300" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A new chromosomal instability disorder: the Nijmegen breakage syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11093281" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10398434" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33488600" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Geographical Distribution, Incidence, Malignancies, and Outcome of 136 Eastern Slavic Patients With Nijmegen Breakage Syndrome and NBN Founder Variant c.657_661del5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18724061" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nijmegen breakage syndrome and functions of the responsible protein, NBS1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19635536" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical variability and expression of the NBN c.657del5 allele in Nijmegen Breakage Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9590181" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910469" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19804755" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nbs1 flexibly tethers Ctp1 and Mre11-Rad50 to coordinate DNA double-strand break processing and repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19782649" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : NBS1 cooperates with homologous recombination to counteract chromosome breakage during replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667076" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The mre11 complex and the response to dysfunctional telomeres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633651" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Multiple roles for MRE11 at uncapped telomeres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19126654" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The DNA repair protein NBS1 influences the base excision repair pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15279809" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7808977" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Postmortem findings in the Nijmegen breakage syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10663471" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cranial MRI in the Nijmegen breakage syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19105185" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fertility defects revealing germline biallelic nonsense NBN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444919" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High prevalence of primary ovarian insufficiency in girls and young women with Nijmegen breakage syndrome: evidence from a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250427" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nijmegen breakage syndrome associated with porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347309" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cutaneous noncaseating granulomas associated with Nijmegen breakage syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28791007" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prospective Study of a Cohort of Russian Nijmegen Breakage Syndrome Patients Demonstrating Predictive Value of Low Kappa-Deleting Recombination Excision Circle (KREC) Numbers and Beneficial Effect of Hematopoietic Stem Cell Transplantation (HSCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30209074" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Nijmegen Breakage Syndrome Complicated With Primary Pulmonary Granulomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30607663" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rubella Virus-Associated Cutaneous Granulomatous Disease: a Unique Complication in Immune-Deficient Patients, Not Limited to DNA Repair Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10799436" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nijmegen breakage syndrome. The International Nijmegen Breakage Syndrome Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26271390" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options - a Retrospective Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33082212" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18788073" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19908051" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Heterozygous germ-line mutations in the NBN gene predispose to medulloblastoma in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18593981" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mutations in the Nijmegen breakage syndrome gene in medulloblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19616740" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical radiation sensitivity with DNA repair disorders: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2342514" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18073374" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cancer risk of heterozygotes with the NBN founder mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19452044" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : NBS1 Heterozygosity and Cancer Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36806726" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The NBN founder mutation-Evidence for a country specific difference in age at cancer manifestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19782616" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Oral findings in patients with Nijmegen breakage syndrome: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19782616" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Oral findings in patients with Nijmegen breakage syndrome: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7545870" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Eleven Polish patients with microcephaly, immunodeficiency, and chromosomal instability: the Nijmegen breakage syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390322" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Heterogeneity of humoral immune abnormalities in children with Nijmegen breakage syndrome: an 8-year follow-up study in a single centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378756" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Loss of juxtaposition of RAG-induced immunoglobulin DNA ends is implicated in the precursor B-cell differentiation defect in NBS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851427" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The defect in humoral immunity in patients with Nijmegen breakage syndrome is explained by defects in peripheral B lymphocyte maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28000062" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Circulating T Cells of Patients with Nijmegen Breakage Syndrome Show Signs of Senescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32695108" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : T Lymphocytes in Patients With Nijmegen Breakage Syndrome Demonstrate Features of Exhaustion and Senescence in Flow Cytometric Evaluation of Maturation Pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2786340" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Further delineation of the Nijmegen breakage syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6828038" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hypersensitivity to ionizing radiation, in vitro, in a new chromosomal breakage disorder, the Nijmegen Breakage Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25677497" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Nijmegen breakage syndrome detected by newborn screening for T cell receptor excision circles (TRECs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451479" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The clinical and biological overlap between Nijmegen Breakage Syndrome and Fanconi anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19409520" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351188" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Growth retardation and immunodeficiency in a patient with mutations in the DNA ligase I gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19467349" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ligase IV syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16439204" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18157127" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28392333" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32602054" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treosulfan-Based Conditioning Regimen in Haematopoietic Stem Cell Transplantation with TCRαβ/CD19 Depletion in Nijmegen Breakage Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19684627" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Successful SCT for Nijmegen breakage syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167538" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Nijmegen breakage syndrome: Long-term monitoring of viral and immunological biomarkers in peripheral blood before development of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18568480" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19125088" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Successful treatment of hodgkin lymphoma in nijmegen breakage syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937313" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18186968" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26826318" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical course and therapeutic implications for lymphoid malignancies in Nijmegen breakage syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
